Intelligence / Thymosin Alpha-1

Thymosin Alpha-1

Prescription Only
Immune Modulator
Schedule
S4
Prescription Only
Enforcement
Stable
Low Risk
Providers
6
Access: Limited
Key Facts
Schedule 4 - Prescription Only
Thymus-derived immune modulating peptide
6 identified Australian providers
Niche but stable availability
No anticipated regulatory changes

Overview

Thymosin Alpha-1 is a peptide fragment of prothymosin alpha, naturally produced by the thymus gland. It is a niche prescription peptide in Australia, available through select telehealth providers and compounding pharmacies.

Australian Scheduling

Schedule 4 (Prescription Only). Stable classification with no anticipated regulatory changes. Available through standard compounding pharmacy pathways.

Access Pathway

Available through select telehealth providers. 6 identified Australian providers. Not as widely available as growth hormone secretagogues or tissue repair peptides, but access is stable.

Regulatory Notice

For informational purposes only. TGA scheduling may change without notice. All Schedule 4 peptides require a valid prescription from a registered Australian medical practitioner. This site does not sell, supply, or facilitate access to therapeutic goods. Data compiled from TGA SUSMP, public provider directories, and publicly available review platforms.

News & Updates15 items
Clinical Applications and Evidence Landscape of Thymosin Alpha 1 as an Immunomodulatory Adjunct in Cancer Care: A Scoping Review
Pharmaceuticals (Basel)19 Sept 2026
Thymosin-ɑ1 for people with chronic hepatitis B
Cochrane Database Syst Rev9 Sept 2026
Thymosin Alpha-1 Provides Direct Neuroprotection by Engaging the Orexin Receptor HCRTR1 to Suppress Neuronal Necroptosis
Adv Sci (Weinh)3 Sept 2026
Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells
Cancer Res2 Sept 2026
Thymosin α-1 in Cancer Therapy: Immunomodulatory Mechanisms, Clinical Applications, and Translational Perspectives
Eur J Pharmacol25 Aug 2026
Regarding IL-15 Plus Thymosin α1 Reduces Senescent Hepatic CD8+ T Cells in Hepatocellular Carcinoma via PI3K/AKT Suppression
J Gastroenterol Hepatol1 July 2026
Thymosin α1 Augments CD8⁺ T-Cell Activation and Reverses Exhaustion In Vitro
Asian Pac J Cancer Prev1 June 2026
Thymosin α1 combined with immune checkpoint inhibitors: synergistic remodeling of the tumor immune microenvironment to enhance clinical efficacy and safety
Front Immunol29 May 2026
IL-15 Plus Thymosin α1 Reduces Senescent Hepatic CD8(+) T Cells in Hepatocellular Carcinoma via PI3K/AKT Suppression
J Gastroenterol Hepatol1 May 2026
Thymalfasin (Thymosin Alpha 1) as an Enhancer of Immunotherapy
ClinicalTrials.gov1 Jan 2025
Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials
PubMed1 Feb 2024
Phenotypic drug discovery: a case for thymosin alpha-1
Frontiers in Medicine1 Jan 2024
Thymosin alpha 1: A comprehensive review of the literature
PMC23 Dec 2020
Immune Modulation with Thymosin Alpha 1 Treatment
PubMed1 July 2016
Thymosin alpha 1: past clinical experience and future promise
PubMed1 June 2010

Are You a Practitioner?

List your clinic for free and reach patients actively searching for legal peptide access in Australia.